Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.